Increased MAPK expression and activity in primary human hepatocellular carcinoma.
about
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progressionOver-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosisPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionTargeted therapy for hepatocellular carcinoma: novel agents on the horizonSelective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell linesTumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafishTAMH: A Useful In Vitro Model for Assessing Hepatotoxic MechanismsPredicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes.Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling.Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling.Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis.Hepatitis C virus (HCV) and lymphomagenesis.Chemically induced mouse liver tumors are resistant to treatment with atorvastatin.An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies.Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125miTALOS v2: Analyzing Tissue Specific microRNA FunctionInduction of hepatocellular carcinoma by in vivo gene targeting.Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK SignalingThe MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.Rodent models of alcoholic liver disease: of mice and men.Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance.Development of a conditional liver tumor model by mifepristone-inducible Cre recombination to control oncogenic kras V12 expression in transgenic zebrafish.Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cellsCurrent insights on the biology and clinical aspects of VEGF regulation.Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.Emerging Raf inhibitors.Targeted therapy of hepatocellular cancer.Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile.
P2860
Q24647547-4057460E-A281-4E47-B18D-519387CAB019Q24805089-14CE8126-8A9B-48FF-802C-156F44180628Q26738860-DDDEE5EA-BCBC-4AE2-9DEB-49282188146FQ27002288-66116AB3-3574-4E65-89D9-8C63F9A22BFAQ28344057-33E145A4-87CD-4D63-9AAF-3DA3A9E1392AQ28368422-D5FBD010-55B2-4924-B079-468007B7B166Q28393439-2702BAB3-B50A-433D-93E7-C3972CB694DBQ28818435-F602EF94-E09F-41BC-80E7-C84F6960A55BQ33496309-4EB4024B-91BB-4502-AAF2-AE7A2A809E0DQ33848045-9A3D76F1-6405-4492-BE02-6A726CDC32E7Q33959204-E93ED6EF-33EE-4808-A433-ABF42BB2CB5FQ34201053-E2E365B2-DFA5-4342-9992-F79F8D0A6200Q34307356-A1C21E41-77F2-4EA3-B210-6C2E8612026AQ34449889-60458A5C-9DDD-403D-A510-A4C76DE94588Q34611577-EB847EFC-25B0-486D-A8E2-E6B37278A1B6Q34632966-F311E27B-3A97-4B01-BFB4-088C2CFE1FBFQ34846215-F5A26316-1D33-4FC0-B09A-063018AA90CDQ35023451-20CD90C0-DCEE-4B5A-949E-2717A8F15EC0Q35081944-13B63E8B-2EDE-4659-BDD1-D1A21C127832Q35197463-E5C71FE6-B404-460B-A5F0-97242ED89678Q35198912-1661074E-5992-4877-863C-756245C8FB73Q35335391-CC92FA2A-A96E-477D-9077-F0FDD1E70517Q35665032-71B94A36-C93A-496D-9FD0-6F2A03FD580EQ35679353-53901235-856F-43E8-AE2F-910BB04747D5Q35894374-2098491D-27FD-467B-9C5A-15D7549E6EB3Q35911859-93E9397E-CEEC-4BA3-B185-9B390CA0BB57Q35943777-E52608E9-07E7-481A-A016-A7A12956572EQ35964688-18796696-AD19-4E45-BD2F-19B09A5A3DDEQ36094151-2F8922F2-C804-4A15-A279-6661317014C5Q36271326-FC0E495A-D60D-4021-BB7A-9445AF7969CDQ36362544-0A45DD6F-3B32-4C3B-A3D5-A949B341766BQ36395131-534F6EC2-C748-4C7B-9C3D-1DEDE3876C8DQ36397319-3E3248F2-4174-4C11-B432-B5FE7F87B8D3Q36501027-EE752632-99B8-4AE9-86FF-873AB1753670Q36996036-046CA0B8-6385-42BB-9432-B729214B1233Q37272329-FDE3AE81-01D5-4DB3-B671-7ED18730F6BDQ37285551-86073EC4-AF6E-46A8-A2DA-0D7C43324A78Q37588717-776D1E2C-0EA7-4C2A-8432-D9FB8EAB4F4DQ37674624-E639652A-A8E1-41C9-A3E8-0DD75CE6A6DEQ37682244-FE7E1A4C-64EF-428D-BED5-5FAD151F2800
P2860
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@ast
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@en
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@nl
type
label
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@ast
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@en
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@nl
prefLabel
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@ast
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@en
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@nl
P2093
P356
P1476
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
@en
P2093
McKillop IH
Schmidt CM
Sitzmann JV
P356
10.1006/BBRC.1997.6840
P407
P577
1997-07-01T00:00:00Z